ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Insulin Glargine

Also written as “insulin glargine”, “Insulin glargine” and “INSULIN GLARGINE”.

Its studies are mostly in Diabetes Mellitus, Type 2 · Diabetes Mellitus, Type 1 · Diabetes Mellitus · Hyperglycemia · Glucose Intolerance, led by 9 companies.

Drug pageInsulin Glargine: every studyMany companies study it; this page follows only the 184 they lead. All 294 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Sep 9, 2005184 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofiits history only1241 open or runningphase 4since Sep 9, 2005Sep 30, 2002none ahead
Novo Nordisk280 open or runningphase 4since Sep 12, 2005Oct 29, 2004none ahead
Eli Lillyits history only250 open or runningphase 4since Sep 12, 2005Sep 12, 2005none ahead
Diabetes Care Centerits history only20 open or runningno phasesince Apr 3, 2007Apr 3, 2007none ahead
Biodelits history only10 open or runningphase 2since Oct 21, 2009Oct 21, 2009none ahead
Geropharmits history only10 open or runningno phasesince Sep 23, 2019Sep 23, 2019none ahead
ikfe-CROits history only10 open or runningphase 4since Dec 5, 2011Dec 5, 2011none ahead
Profil Institut für Stoffwechselforschungits history only10 open or runningphase 1since Sep 3, 2009Sep 3, 2009none ahead
Wockhardtits history only10 open or runningphase 1since May 12, 2011May 12, 2011none ahead

Also a collaborator on its studies: PPD DEVELOPMENT, LP, Alkermes and Boehringer Ingelheim.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Novo Nordisk only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 13 studies since Oct 29, 2004.

  1. Jan 14, 2009Phase 1 study in Diabetes MellitusNCT00824668 · 24 enrolled · Germany
  2. Aug 17, 2009Phase 1 study in Diabetes MellitusNCT00961324 · 54 enrolled · Germany
  3. Oct 26, 2009Phase 1 study in Diabetes MellitusNCT01002768 · 28 enrolled · Austria
  4. Oct 30, 2009Phase 3 study in Diabetes MellitusNCT01006291 · 687 enrolled · Argentina, Finland, Hungary and more
  5. Jan 8, 2010Phase 3 study in Diabetes MellitusNCT01045707 · 530 enrolled · United States, Austria, India and more
  6. May 31, 2010Phase 3 study in Diabetes MellitusNCT01135992 · 143 enrolled · United States
  7. Dec 20, 2011Phase 1 study in Diabetes MellitusNCT01497574 · 32 enrolled · Germany
  8. Apr 2, 2012Phase 3 study in Diabetes MellitusNCT01570751 · 145 enrolled · United States, Puerto Rico
  9. Oct 8, 2012Phase 1 study in Diabetes MellitusNCT01704417 · 40 enrolled · Germany
  10. Nov 6, 2012Phase 1 study in Diabetes MellitusNCT01730014 · 70 enrolled · Germany
  11. May 6, 2013Phase 3 study in Diabetes MellitusNCT01849289 · 833 enrolled · United States, Brazil, Canada and more
  12. May 30, 2013Phase 1 study in Diabetes MellitusNCT01868529 · 63 enrolled · Germany
  13. Jan 7, 20142 phase 3 studies in Diabetes MellitusNCT02034513, NCT02030600
  14. Mar 26, 2024Phase 3 study in Diabetes Mellitus, Type 2NCT06340854 · 412 enrolled · United States, Bulgaria, Germany and more

TargetBeta

INSR →read by rule
“Insulin receptor agonist”ChEMBL 37, by rule

Other programs on INSR

ProgramCompanyFurthest phaseStudies
Insulin AspartruleNovo Nordiskphase 4146
insulin degludecruleNovo Nordiskphase 4108
InsulinrulePfizerphase 450
insulin glulisineruleSanofiphase 443
insulin icodecruleNovo Nordiskphase 430
linsitinibruleAstellas Pharmaphase 313
LY3938577Eli Lillyphase 23

Studies

All 28 Novo Nordisk leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06340854Diabetes Mellitus, Type 2 · United States, Bulgaria, Germany and more3CompletedMay 8, 2025412
NCT02034513Diabetes Mellitus · United States, Poland, Puerto Rico3CompletedJan 11, 2016501
NCT02030600Diabetes Mellitus · United States, Puerto Rico3CompletedDec 4, 2015721
NCT01868529Diabetes Mellitus · Germany1CompletedJun 200863
NCT01849289Diabetes Mellitus · United States, Brazil, Canada and more3CompletedMay 15, 2014833
NCT01730014Diabetes Mellitus · Germany1CompletedJul 201370
NCT01704417Diabetes Mellitus · Germany1CompletedMar 201340
NCT01570751Diabetes Mellitus · United States, Puerto Rico3CompletedJan 2014145
NCT01497574Diabetes Mellitus · Germany1CompletedOct 200532
NCT01135992Diabetes Mellitus · United States3CompletedNov 2010143
NCT01045707Diabetes Mellitus · United States, Austria, India and more3CompletedOct 2010530
NCT01006291Diabetes Mellitus · Argentina, Finland, Hungary and more3CompletedSep 2010687
NCT01002768Diabetes Mellitus · Austria1CompletedMar 201028
NCT00961324Diabetes Mellitus · Germany1CompletedOct 26, 200954
NCT00824668Diabetes Mellitus · Germany1CompletedOct 200724
NCT00619697Diabetes Mellitus · Austria, Czech Republic, Germany and more4CompletedMar 2005260
NCT00612040Diabetes Mellitus · United States, Australia, Germany and more2CompletedJun 2008178
NCT00598793Diabetes Mellitus · United States3CompletedMar 2004242
NCT00331851Diabetes Mellitus · Argentina, Austria, Brazil and more3CompletedApr 2007584
NCT00313742Diabetes Mellitus · Germany, United Kingdom4CompletedNov 200651
NCT00312104Diabetes Mellitus · Austria, Germany, South Africa3CompletedMar 2003325
NCT00283751Diabetes Mellitus · United States, Austria, Belgium and more3CompletedNov 2004583
NCT00184626Diabetes Mellitus · Turkey4CompletedOct 24, 200597
NCT00184613Diabetes Mellitus · Denmark1CompletedJan 200622
NCT00106366Diabetes Mellitus · United States, Canada, Puerto Rico3CompletedDec 2005389
NCT00097877Diabetes Mellitus · United States, Puerto Rico3CompletedNov 2006293
NCT00097084Diabetes Mellitus · United States, Finland, France and more3CompletedDec 2005324
NCT00095082Diabetes Mellitus · United States, Finland, France and more3CompletedDec 2005447

How it is read

Names in the registry

  • “insulin glargine”, 38 entries
  • “Insulin Glargine”, 27 entries
  • “Insulin glargine”, 20 entries
  • “INSULIN GLARGINE”, 15 entries
  • “LY2963016”, 11 entries

Codes read as this program: HOE901.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.